Journal of Modern OncologyJournal of Modern OncologyСовременная онкология1815-14341815-1442LLC Obyedinennaya Redaktsiya29504ArticlesСтатьиFulvestrant - endokrinnaya terapiya rasshirennogo spektra deystviyaФулвестрант - эндокринная терапия расширенного спектра действияMeshcheryakovA AМещеряковА А

ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва

ФГБУ Российский онкологический научный центр им. Н.Н.Блохина РАМН, Москва15092012143NO3 (2012)ТОМ 14, №3 (2012)374009042020Copyright ©; 2012, Consilium MedicumCopyright ©; 2012, ООО "Консилиум Медикум"2012Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc/4.0https://modernonco.orscience.ru/1815-1434/article/view/29504

1. Huang HJ, Neven P, Drijkoningen M et al. Association between tumour characteristics and HER-2/neuby immunohistochemistry in 1362 women with primary operable breast cancer. J Clin Pathol 2005; 58: 611-6.2. Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res 1991; 51: 3867-73.3. Krell J, Januszewski A, Yan K et al. Role of fulvestrant in the management of postmenopausal breast cancer. Expert Rev Anticancer Ther 2011; 11 (11): 1641-52.4. Di Leo A, Jerusalem G, Petruzelka LJ et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010; 28 (30): 4594-600.5. Ohno S, Rai Y, Iwata H et al. Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1). Ann Oncol 2010; 21 (12): 2342-7.6. Pritchard KI, Rolski J, Papai Z. Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2). Breast Cancer Res Treat 2010; 123 (2): 453-61.7. Kuter I, Gee JM, Hegg R et al. Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study. Breast Cancer Res Treat 2012; 133 (1): 237-46.8. Robertson JF, Llombart-Cussac A, Rolski J et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol 2009; 27 (27): 4530-5.9. A phase III randomized trial of anastrozole versus anastrozole and fulvestrant as first-line therapy for postmenopausal women with metastatic breast cancer, CTRC-AACR San Antonio Breast Cancer Symposium 2011.10. Mehta RS, Barlow WE, Albain KS et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med 2012; 367: 435-44.11. Bergh J, Jönsson PE, Lidbrink EK et al. FACT: An Open-Label Randomized Phase III Study of Fulvestrant and Anastrozole in Combination Compared With Anastrozole Alone As First-Line Therapy for Patients With Receptor-Positive Postmenopausal Breast Cancer J Clin Oncol 2012; 30 (16): 1919-25.12. Bartsch R, Bago-Horvath Z, Berghoff et al. Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer. Eur J Cancer 2012.13. Robertson JF, Steger GG, Neven P et al. Activity of fulvestrant in HER2-overexpressing advanced breast cancer. Ann Oncol 2010; 21 (6): 1246-53.14. Barrios C, Forbes JF, Jonat W et al. The sequential use of endocrine treatment for advanced breast cancer: where are we? Ann Oncol 2012; 23: 1378-86.15. Masci G, Gandini C, Zuradelli M et al. Fulvestrant for advanced male breast cancer patients: a case series. Ann Oncol 2011; 22: 985-93.16. Ikeda H, Taira N, Nogami T et al. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer. Cancer Sci 2011; 102 (11): 2038-42.17. Sui M, Jiang D, Hinsch C et al. Fulvestrant (ICI 182, 780) sensitizes breast cancer cells expressing estrogen receptor alpha to vinblastine and vinorelbine. Breast Cancer Res Treat 2010; 121 (2): 335-45.18. Aurilio G, Munzone E, Botteri E et al. Oral Metronomic Cyclophosphamide and Methotrexate Plus Fulvestrant in Advanced Breast Cancer Patients: A Mono-Institutional Case-Cohort Report Breast J 2012; 10 (1111): 1524-41.19. Xu R, Shen H, Guo R et al. Combine therapy of gefitinib and fulvestrant enhances antitumor effects on NSCLC cell lines with acquired resistance to gefitinib. Biomed Pharmacother 2012; 66 (5): 384-9.20. Klinge CM. Inhibition of non-small-cell lung cancer growth by combined fulvestrant and vandetanib. Future Oncol 2012; 8 (5): 529-33.21. Rajoria S, Suriano R, George AL et al. Molecular target based combinational therapeutic approaches in thyroid cancer. J Transl Med 2012; 10: 81.